Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191202 | 0.93 | MAOB (0.47) | DYRK1ALMNAKCNH2EGFRPIK3CA | |
| SCHEMBL24450228 | 0.85 | LMNA (0.40) | DYRK1ALMNAKCNH2MAOBMAPT | |
| SCHEMBL22191163 | 0.83 | DYRK1A (0.47) | DYRK1ALMNAPGRMAOBMAPT | |
| SCHEMBL22191707 | 0.83 | PGR (0.52) | LMNAKCNH2EGFRPIK3CAPGR | |
| SCHEMBL22191227 | 0.82 | PDE3B (0.47) | KCNH2EGFRPIK3CACYP11B2KDR | |
| SCHEMBL22191137 | 0.81 | PGR (0.50) | KCNH2EGFRPIK3CAPGRMAOB | |
| SCHEMBL22191544 | 0.81 | PGR (0.46) | DYRK1ALMNAKCNH2EGFRPIK3CA | |
| SCHEMBL24450304 | 0.79 | HTR7 (0.42) | KCNH2EGFRPIK3CAPGRCYP11B2 | |
| SCHEMBL22191255 | 0.79 | PGR (0.46) | KCNH2PGRCYP11B2AKT1 | |
| SCHEMBL22191401 | 0.79 | GAA (0.46) | DYRK1ALMNAPGRMAOBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| EP-3906233-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113508111-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2021-10-15 | — | — | CN | disclosed |
| WO-2020142485-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | DYRK1A 481/4885LMNA 2072/4885KCNH2 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.